Navigation Links
Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study
Date:9/13/2007

SIMPLIFI to Examine Single-Dose and Infrequent-Dosing Regimens in cSSSI

CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Targanta Therapeutics Corporation today announced the initiation of its Phase 2 trial investigating the safety and efficacy of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI. Oritavancin is Targanta's lead antibiotic candidate targeting gram- positive infections.

This Phase 2 study is an international, multi-center, randomized, double- blind, controlled study in patients with cSSSI presumed or proven to be caused by gram-positive pathogen(s). The study consists of three treatment arms in which patients will receive either:

-- 200 mg oritavancin IV daily for a minimum of 3 days and up to a maximum

of 7 days (the dosing regimen used in the larger of the two completed

Phase 3 studies of oritavancin in cSSSI);

-- A single dose of 1200 mg oritavancin IV; or

-- A single dose of 800 mg oritavancin IV, with a further dose of 400 mg

IV on Day 5 if needed.

As its primary endpoint, SIMPLIFI will measure clinical response (either cure or improvement versus failure) in clinically evaluable patients. As a secondary endpoint, this study will examine safety data in all intent-to-treat patients. Targanta expects to enroll a total of 300 patients in this study.

"Based on extensive pharmacokinetic and pharmacodynamic modeling, we believe there is a high likelihood of success with the less frequent oritavancin dosing regimens being studied here," said Pierre E. G. Etienne, M.D. Chief Development Officer of Targanta. "We currently expect to complete collection of clinical trial data from SIMPLIFI in the second half of 2008, at which time we will assess the outcomes and determine whether to pursue Phase 3 registration trials. In the meantime, we are working on the preparation of our first U.S. and European regulatory s
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... PARIS , May 6, 2015 ... the development and manufacture of filtration products, mainly for ... ZenPure designs custom filters manufactured in a state-of-the-art plant ... are marketed and sold across the globe and will ... Plastics business. This acquisition is fully in ...
(Date:5/6/2015)... , May 6, 2015  Membership in Medicare Supplement ... a Healthcare Business Strategy report released by Mark ... as Medigap or Med Supp plans, covered approximately ... a 5.2% increase from 2013. Between 2013 and ... 551,135 covered lives.  Though UnitedHealth was the segment ...
(Date:5/6/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7qn2gf/global_insulin ... "Global Insulin Patch Market Opportunity Analysis" report ... like ultrasound and iontophoresis are being used for ... the type of technique, their prices may vary ... patients. In long-term, it would be considered as ...
Breaking Medicine Technology:Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Global Insulin Patch Market Opportunity Analysis 2015 2
... First Effective Drug for Rare Genetic Disorder in,Children--, ... drug to achieve normal levels of blood sugar ... levels. If this approach,succeeds in humans, it could ... a rare but potentially devastating genetic,disease in which ...
... Pathwork Diagnostics, Gene Expression Test Is the First to Receive FDA, ... ... U.S. Cancer Cases Annually, SUNNYVALE, Calif., July 31 Pathwork ... U.S. Food and Drug Administration (FDA) has cleared its Pathwork(R),Tissue of ...
Cached Medicine Technology:Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 2FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 4
(Date:5/6/2015)... May 06, 2015 Prime Pacific ... is excited to announce a new series of ... the industry’s carbon footprint while improving treatment efficacy ... Eco-Flex™, the world’s first waste hose ... game-changer for hydrotherapists,” claims the company’s president, Mr. ...
(Date:5/6/2015)... “ SideChef ” was featured on NewsWatch as part of its ... applications on the market for iOS, Android, and Windows. Joe Toohey, ... and shared with viewers how this application walks users through recipes. ... good navigator people had to know how to read a map? ... navigator. Well what if people could “GPS” their way through a ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 vcfo, a ... HR, IT and operational support to optimize business performance ... CFOs, Jack Lynch and Michael Scheaffer. Both Lynch and ... and leadership experience. , “We are delighted to ... Wood, vcfo CEO. “Leveraging their background in financial management ...
(Date:5/6/2015)... Healthcare jobs platform, JobMedic.com, has quickly ... The company connects hospitals, home-health, and other medical organizations ... industry. Likewise, job seekers are able to locate jobs ... unique traffic to the site is up more than ... posting brings targeted, interested candidates to the site through ...
(Date:5/6/2015)... The Alliance for Regenerative Medicine (ARM), ... advanced therapies community, today announced the release of ... look at sector trends and metrics from the ... is available online here and also ... here . , Using information provided by ...
Breaking Medicine News(10 mins):Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:An Application to Guide Users through Recipes Was Featured on NewsWatch Television 2Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 3
... seem largely visual the preening, the coy eye contact ... voice may be a means of demonstrating attraction, says Susan ... Pa., in a study, "Vocal and Physiological Changes in Response ... in the fall by the Journal of Nonverbal Behavior ...
... ... play weather, the National Recreation and Park Association (NRPA) is reminding Americans to take the ... To assist, NRPA has published The Dirty Dozen, a comprehensive brochure and playground-safety resource ... ...
... ... Patient Satisfaction Conference June 4th 2010. Expert speakers will discuss improving communications between caregivers, ... , ... 2010 -- Scan Am Company of Algonquin, Illinois, will be hosting a Patient Safety ...
... and when they were readmitted , THURSDAY, May 20 ... disease who decide to discharge themselves before their doctors ... and when they are readmitted. , The finding, set ... for Pharmacoeconomics and Outcomes Research meeting in Atlanta, comes ...
... Gastroesophageal reflux (GER), defined as passage of gastric contents ... in healthy infants, children and adults. When GER causes ... gastroesophageal reflux disease (GERD). During infancy, GER is common ... non-specific symptoms as irritability and cough. Association of non-specific ...
... a study published today in the journal Addiction , ... effective among people with severe mental illnesses as it is ... offering such treatments does not appear to cause deterioration in ... severe mental illnesses (SMI) such as schizophrenia have some of ...
Cached Medicine News:Health News:The sound of seduction 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 3Health News:Patient Safety and Satisfaction are Key Issues at Scan Am Company June Conference 2Health News:When Heart Patients Discharge Themselves, Hospital Bills Increase 2Health News:Disagreement on symptom-reflux association analysis parameters in infants 2Health News:Smoking cessation treatments work and are safe for people with severe mental illness 2